Switch theme
Sign up to access all valuation multiples
Alkaloid AD Skopje is engaged in producing and selling pharmaceutical, chemical and cosmetic products, as well as goods from the herbal origin. Its segments are Pharmaceuticals, Chemicals, Cosmetics and Botanicals. It derives maximum revenue from Pharmaceuticals products segment.
1936
3.0K+
Last FY Revenue $349M
Last FY EBITDA $36.6M
$722M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, Alkaloid achieved revenue of $349M and an EBITDA of $36.6M.
Alkaloid expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Alkaloid valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | $349M | XXX | XXX | XXX |
| Gross Profit | XXX | $158M | XXX | XXX | XXX |
| Gross Margin | XXX | 45% | XXX | XXX | XXX |
| EBITDA | XXX | $36.6M | XXX | XXX | XXX |
| EBITDA Margin | XXX | 10% | XXX | XXX | XXX |
| EBIT | XXX | $41.6M | XXX | XXX | XXX |
| EBIT Margin | XXX | 12% | XXX | XXX | XXX |
| Net Profit | XXX | $31.0M | XXX | XXX | XXX |
| Net Margin | XXX | 9% | XXX | XXX | XXX |
| Net Debt | XXX | $32.8M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Alkaloid's stock price is MKD 26600 (or $489).
Alkaloid has current market cap of MKD 37.5B (or $689M), and EV of MKD 39.3B (or $722M).
See Alkaloid trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $722M | $689M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Alkaloid has market cap of $689M and EV of $722M.
Alkaloid's trades at 2.1x EV/Revenue multiple, and 19.7x EV/EBITDA.
Equity research analysts estimate Alkaloid's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Alkaloid's P/E ratio is not available.
See valuation multiples for Alkaloid and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $689M | XXX | $689M | XXX | XXX | XXX |
| EV (current) | $722M | XXX | $722M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | 2.1x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | 19.7x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | 17.3x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | 22.3x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 83.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialAlkaloid's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $38K for the same period.
Alkaloid's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Alkaloid's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Alkaloid and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | 10% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $38K | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 29% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 1% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 33% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Alkaloid acquired XXX companies to date.
Last acquisition by Alkaloid was XXXXXXXX, XXXXX XXXXX XXXXXX . Alkaloid acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Alkaloid founded? | Alkaloid was founded in 1936. |
| Where is Alkaloid headquartered? | Alkaloid is headquartered in Macedonia. |
| How many employees does Alkaloid have? | As of today, Alkaloid has 3.0K+ employees. |
| Is Alkaloid publicy listed? | Yes, Alkaloid is a public company listed on MAE. |
| What is the stock symbol of Alkaloid? | Alkaloid trades under ALK ticker. |
| Who are competitors of Alkaloid? | Similar companies to Alkaloid include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Alkaloid? | Alkaloid's current market cap is $689M |
| Is Alkaloid profitable? | Yes, Alkaloid is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
